TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$10 Million

Catabasis Pharmaceuticals

At-the-market Offering

Catabasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker drug discovery platform. Catabasis’ SMART linker drug discovery platform enables the Company to engineer product candidates that can simultaneously modulate multiple targets in a disease. The Company’s proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. The Company’s primary focus is on treatments for rare diseases. Catabasis is also developing other product candidates for the treatment of serious lipid disorders. The Company has applied its SMART linker drug discovery platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates